Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002
Urinary N-acetil-beta-glucosaminidase in the evaluation of antituberculous treatment Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
The oxidative stress determination on patients trated with tuberculostatic drugs Source: Eur Respir J 2003; 22: Suppl. 45, 154s Year: 2003
Cardiotoxicity of a complex of anti-tuberculosis drugs with the inclusion of fluoroquinolones and bedaquiline in an experiment on rats Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021
Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Inhaled anticholinergic drugs and risk of acute urinary retention Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005
Hepatotoxic reactions in rats after administration of component schemes of reserve Anti-TB drugs with different safety profile Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017